URO ONCO

Welcome, this website is intended for all international healthcare professionals in uro-oncology. By clicking the link below you are declaring and confirming that you are a healthcare professional.

You are here

Prostate cancer proteomics: Current trends and future perspectives for biomarker discovery

Tanase CP, Codrici E, Popescu ID, Mihai S, Enciu AM, Necula LG, et al.

Abstract

The clinical and fundamental research in prostate cancer - the most common urological cancer in men - is currently entering the proteomic and genomic era. The focus has switched from one single marker (PSA) to panels of biomarkers (including proteins involved in ribosomal function and heat shock proteins). Novel genetic markers (such as Transmembrane protease serine 2 (TMPRSS2)-ERG fusion gene mRNA) or prostate cancer gene 3 (PCA3) had already entered the clinical practice, raising the question whether subsequent protein changes impact the evolution of the disease and the response to treatment. Proteomic technologies such as MALDI-MS, SELDI-MS, i-TRAQ allow a qualitative/quantitative analysis of the proteome variations, in both serum and tumor tissue. A new trend in prostate cancer research is proteomic analysis of prostasomes (prostate-specific exosomes), for the discovery of new biomarkers. This paper provides an update of novel clinical tests used in research and clinical diagnostic, as well as of potential tissue or fluid biomarkers provided by extensive proteomic research data.

KEYWORDS: biomarkers; mass spectrometry; prostasomes; prostate cancer; proteomics

PMID: 28061466

DOI: 10.18632/oncotarget.14501

Editorial comment from Piotr Chlosta:
This paper provides an overview of current most promising biomarkers identified with the new -omics technologies to help physicians in clinical decision making for PCa diagnosis, prognosis and prediction of therapeutic effect.